Asian Journal of Chemistry

Vol. 20, No. 7 (2008), 5161-5165

# Synthesis and Antimicrobial Activity of 6,7,8,9-Tetrahydro-5(*H*)-5-nitrophenylthiazolo[2,3-b]quinazoline-3(2*H*)-one Derivatives

P. PRAVEEN KUMAR\*, Y. RAJENDRA PRASAD<sup>†</sup>, N.R. KUMAR<sup>‡</sup> and S. SRIDHAR Department of Pharmaceutical Chemistry Hindu College of Pharmacy, Guntur-522 002, India E-mail: praveen\_p26@yahoo.co.in

> 6,7,8,9-Tetrahydro-5(H)-5-nitrophenylthiazolo[2,3-b]quinazolin-3-(2H)-one (2) has been synthesized as intermediate from 3,4,5,6,7,8-hexahydro-4-nitro phenyl quinazolin-2-thione (1) with chloro acetic acid. The treatment of intermediate with various aldehyde afforded respective benzylidine derivatives (**3a-c**). This on further treatment with phenyl hydrazine yielded hydrazine derivatives (**4a-c**). The structures of the compounds were supported by spectral data. The synthesized compounds have been screened for antimicrobial activity.

> Key Words: Synthesis, Antimicrobial activity, Phenyl hydrazine, Quinazolines.

#### **INTRODUCTION**

The bridge-head nitrogen containing compounds are emerging an important medicinal agent and have been reported<sup>1</sup> to posses wide range of biological accessibility and known to exhibit potent antimicrobial activity, analgesic and antiinflammatory activity, *etc*. Several reports are available regarding the antimicrobial, analgesic and antiinflammatory activity of quinazoline derivatives and the importance of benzylidine and hydrazine in antimicrobial, analgesic and antiinflammatory effect. Hence, the present work has been directed on designing of benzylidine and hydrazine derivatives of quinazoline.

In present work, 6,7,8,9-tetrahydro-5(*H*)-5-nitro phenyl thiazolo[2,3-b]quinazolin-3(2*H*)-one (**2**) has been synthesized by treating 3,4,5,6,7,8-hexahydro-4-nitro phenylquinazolin-2-thione<sup>2,3</sup> (**1**) with chloro acetic acid followed by thermal cyclization gives intermediate **2** compound. The treatment of

 $<sup>\</sup>dagger Department$  of Pharmaceutical Chemistry, Andhra University, Visakhapatnam-530 003, India.

<sup>‡</sup>Department of Pharmaceutical Chemistry, C.L. Baid Metha College of Pharmacy, Chennai-600 097, India.

5162 Kumar et al.

Asian J. Chem.

intermediate **2** with different aldehyde afforded benzylidine derivatives **3a-c**, respectively. The yielded derivatives of benzylidine, on treatment with phenyl hydrazine yielded **4a-c**.

### **EXPERIMENTAL**

Melting points of all the synthesized compounds were determined by using open capillary method and are uncorrected. The precoated alumina plates with silica gel GF<sub>254</sub> (E.Merck) were used for purity determination and pet.ether:ethyl acetate (1:2) was employed as irrigant. IR spectra were recorded (cm<sup>-1</sup>) on ABB BOMEM FT-IR spectrometer using KBr pellet technique, <sup>1</sup>H NMR was recorded ( $\delta$  ppm) on BUKER AV 400 using TMS as internal standard and Mass spectra (EI) were recorded on GCMS QP 5000 Shimadzu.

**Synthesis of 3a-c:** An equimolar quantities of compound **2** (0.015 mol) and respective aldehydes (0.015 mol) and anhydrous sodium acetate (6 g) in glacial acetic acid was taken in 500 mL round bottomed flask fitted with double surface condenser with a guard tube and was heated under reflux for 8-10 h. The reaction mixture was kept overnight for crystallization. The formed crystals were filtered and recrystallized to give **3a-c**. The purity of the all synthesized compounds were established on TLC plate. The physical data were presented in Table-1.

1111010111111		( <b>eu e</b> )
Compd.	m.p. (°C)	Yield (%)
<b>3</b> a	116-118	42.55
<b>3</b> b	143-145	50.00
3c	216-218	47.22
50	210-210	77.22

TABLE-1 PHYSICAL DATA OF THE SYNTHESIZED COMPOUNDS (**3a-c**)


**Compound 3a:** 2-(*o*-Hydroxy benzylidine)-5(*H*)-5-nitro phenyl-6,7, 8,9-tetrahydro thiazolo[2,3-b]quinazolin-3-one, yield-42.55 %, m.p. 116-118 °C; IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 1715 (C=O), 1644, 1525, 1580 (C=N & C=C), 3650 (-OH), 1486 (N=O); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 5.471 (1H, S, C-H), 2.032-2.321 (8H, m, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 6.879-7.759 (8H, m, Ar) 8.131 (1H, S, =CH), 4.112 (1H, S, OH); Mass (EI): m/e 433 (2 %, M<sup>+</sup>) m/e 95 (100 % base peak).

**Compound 3b:** 2-(*p*-Chloro benzylidine)-5(*H*)-5-nitro phenyl-6,7,8,9-tetrahydro thiazolo[2,3-b]quinazolin-3-one, yield - 42.55 %, m.p. 116-118 °C; IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 1716 (C=O), 1604, 1526 (C=N & C=C), 807 (C-Cl), 1489 (N=O); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 5.567 (1H, S, C-H), 2.019-2.394 (8H, m, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 7.516-7.983 (8H, m, Ar), 8.142 (1H, S, =CH) ; Mass (EI): m/e 433 (2 %, M<sup>+</sup>) m/e 95 (100 % base peak).

Vol. 20, No. 7 (2008) Synthesis & Antimicrobial Activity of Quinazoline-3(2H)-ones 5163

**Compound 3c:** 2-(*p*-Nitro benzylidine)-5(*H*)-5-nitro phenyl-6,7,8,9tetrahydro thiazolo[2,3-b]quinazolin-3-one, yield-42.55 %, m.p. 116-118 °C; IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 1715, (C=O), 1669, 1528 (C=N & C=C), 1486 (N=O); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 3.995 (1H, S, C-H), 1.995-2.283 (8H, m, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 7.287-7.810 (8H, m, Ar), 8.208 (1H, S, =CH); Mass (EI): m/e 433 (2 %, M<sup>+</sup>) m/e 95 (100 % base peak).

**Synthesis of 4a-c:** A mixture of compound **3a-c** (0.00517 mol), phenyl hydrazine and anhydrous sodium acetate in glacial acetic acid was taken in 500 mL round bottomed flask fitted with condenser with a guard tube and was refluxed for 14-22 h. The volume was concentrated to its half and the mixture was kept for 48 h at room temperature for crystallization. The separated product was filtered and recrystallized to yielded **4a-c** (**Scheme-I**). The purity of the all synthesized compounds were established on TLC plate. The physical data were presented in Table-2.



Scheme-I

5164 Kumar et al.

Asian J. Chem.

 TABLE-2

 PHYSICAL DATA OF THE SYNTHESIZED COMPOUNDS (4a-c)

Compd.	m.p. (°C)	Yield (%)
<b>4</b> a	95-97	62.22
<b>4b</b>	155-157	60.00
 <b>4</b> c	185-187	59.50

**Compound 4a:** 2-(*o*-Hydroxy benzylidine)-3-phenylhydrazine-5(*H*) -5-nitro phenyl-6,7,8,9-tetrahydro thiazolo[2,3-b]quinazoline, yield-42.55 %, m.p.116-118 °C; IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 1654, 1525 (C=N & C=C), 3649 (-OH), 1489 (N= O); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 4.276 (1H, S, C-H), 1.608-2.330 (8H, m, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 7.134-7.410 (8H, m, Ar), 7.575 (1H, S, =CH), 1.253 (1H, S, =N-NH), 4.210 (1H, S, OH); Mass (EI): m/e 433 (2 %, M<sup>+</sup>) m/e 95 (100 % base peak).

**Compound 4b:** 2-(*p*-Chloro benzyl indene)-3-phenyl hydrazine-5(*H*)-5-nitro phenyl-6,7,8,9-tetra hydro thiazolo[2,3-b]quinazoline, yield-42.55 %, m.p. 116-118 °C; IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 1654, 1525 (C=N & C=C), 810 (C-Cl), 1489 (N=O); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 5.471 (1H, S, C-H), 2.019-2.381 (8H, m, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 6.989-7.542 (8H, m, Ar), 8.210 (1H, S, =CH), 1.283 (1H, S, =N-NH); Mass (EI): m/e 433 (2 %, M<sup>+</sup>) m/e 95 (100 % base peak).

**Compound 4c:** 2-(*p*-Nitro benzylidine)-3-phenylhydrazine-5(*H*)-5-nitro phenyl-6,7,8,9-tetrahydro thiazolo[2,3-b]quinazoline, yield-42.55 %, m.p. 116-118 °C; IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 1669, 1525 (C=N & C=C), 1490 (N=O); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.817 (1H, S, C-H), 2.091-2.228 (8H, m, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 7.642-7.865 (8H, m, Ar), 1.743 (1H, S, =N-NH); Mass (EI): m/e 433 (2 %, M<sup>+</sup>) m/e 95 (100 % base peak).

Antimicrobial activity: The synthesized compounds were screened for antibacterial activity against *E. coli*, *Klebsiella pneumonia*, *Staphylococcus aureus* and *Staphylococcus epidermis* and antifungal activity against *Aspergillus niger* and *Candida albicans*. Neat samples and serial tube dilution method<sup>4</sup> in DMF were used to determine minimum inhibitory concentration (MIC). The MIC was measured in µg/mL and the activity was compared with ciprofloxacin and ketoconazole<sup>5</sup> as standard for antibacterial and antifungal activity, respectively.

# **RESULTS AND DISCUSSION**

In this study six new 6,7,8,9-tetrahydro-5*H*-5-nitrophenylthiazolo quinazoline-3-one derivatives having aromatic aldehyde and phenyl hydrazine substitution on 6,7,8,9-tetrahydro-5*H*-5-nitrophenylthiazolo quinazoline-3-one ring were synthesized to evaluate antimicrobial activity. An examination of result reveals that all the compounds showed antimicrobial activity ranging from 50 to 200  $\mu$ g/mL. The synthesized compounds antimicrobial data showed in Table-3.

Vol. 20, No. 7 (2008) Synthesis & Antimicrobial Activity of Quinazoline-3(2H)-ones 5165

## TABLE-3 BIOLOGICAL SCREENING DATA OF SYNTHESIZED COMPOUNDS **3a-c**, **4a-c** AT A CONCENTRATION OF 200 µg/mL

Compd.	Antibacterial activity			Antifungal		
_	-			activity		
	EC	KP	SA	SE	AN	CA
3a	16	17	18	20	18	16
3b	15	18	17	18	17	18
3c	16	17	19	18	16	17
<b>4</b> a	24	23	21	25	21	21
<b>4</b> b	23	21	19	20	19	18
<b>4</b> c	24	22	21	24	21	20
Standard (100 µg/mL)	28	25	24	27	24	24
Blank	_	_	_	_	-	_

EC = E. coli; KP = K. pneumonia; SA = S. aureus; SE = S. epidermis; AN = A. niger; CA = C. albicans.

These results clearly demonstrated that the presence of phenyl hydrazine group at 6,7,8,9-tetrahydro-5*H*-5-nitrophenylthiazolo quinazoline-3-one ring cause improvement in antimicrobial activity.

#### ACKNOWLEDGEMENTS

The authors are thankful to IISC, Bangalore and IIT, Chennai for spectral analysis and to the Management, C.L. Baid Metha College of Pharmacy for providing the necessary facilities.

# REFERENCES

- 1. G.D. Gupta and H.K. Pujari, J. Indian Chem. Soc., 51, 2050 (1984).
- 2. R. Sharma, S. Kumar and H.K. Pujari, Indian J. Chem., 30B, 425 (1991).
- 3. A.I. Vogel's, Text of Practical Organic Chemistry, edn. 5, p. 1260 (1989).
- 4. J.G. Collee, J.P. Duguid, M.G. Fraser, B.P. Marmion and M. McCartney, Practical Medical Microbiology, Churchill Livingstone, London, edn. 13, pp. 163-165 (1989).
- 5. Goodman and Gilmans, The Pharmacological Bases of Therapeutics, edn. 9, pp. 1180-1181.

(Received: 7 May 2007; Accepted: 9 April 2008) AJC-6515